Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 24, Issue 1 , Pages 39-50 , February 2010

Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer

  • Nikos F. Vlahos, MD (Assistant Professor)

      Affiliations

    • Tel.: +30 210 728 6353; Fax: +30 210 748 5591.
    • ,
  • Konstantinos P. Economopoulos, MD (Fellow Researcher)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +30 694 2462 812; Fax: +30 210 5593 860.
    • ,
  • Stylianos Fotiou, MD (Associate Professor)

      Affiliations

    • Tel.: +30 210 728 6353; Fax: +30 210 748 5591.

References 

  1. Ozkan S, Murk W, Arici A. Endometriosis and infertility: epidemiology and evidence-based treatments. Ann N Y Acad Sci. 2008;1127:92–100
  2. Lapp T. Acog issues recommendations for the management of endometriosis. American college of obstetricians and gynecologists. Am Fam Physician. 2000;62(1431):1434
  3. Melin A, Sparen P, Persson I, et al. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod. 2006;21:1237–1242
  4. Olson JE, Cerhan JR, Janney CA, et al. Postmenopausal cancer risk after self-reported endometriosis diagnosis in the Iowa women's health study. Cancer. 2002;94:1612–1618
  5. Sampson J. Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch Surg. 1925;10:72
  6. Brinton LA, Gridley G, Persson I, et al. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997;176:572–579
  7. Melin A, Sparen P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Hum Reprod. 2007;22:3021–3026
  8. Sainz de la Cuesta R, Eichhorn JH, Rice LW, et al. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol. 1996;60:238–244
  9. Vercellini P, Parazzini F, Bolis G, et al. Endometriosis and ovarian cancer. Am J Obstet Gynecol. 1993;169:181–182
  10. Vercellini P, Scarfone G, Bolis G, et al. Site of origin of epithelial ovarian cancer: the endometriosis connection. BJOG. 2000;107:1155–1157
  11. Check JH, Check ML, Kiefer D, et al. Ovarian cancer in a woman previously diagnosed with endometriosis and an extremely high serum ca-125 level. Clin Exp Obstet Gynecol. 2001;28:83–85
  12. Erzen M, Kovacic J. Relationship between endometriosis and ovarian cancer. Eur J Gynaecol Oncol. 1998;19:553–555
  13. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol. 2003;189:280–294
  14. Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000;11:111–117
  15. Obata K, Hoshiai H. Common genetic changes between endometriosis and ovarian cancer. Gynecol Obstet Invest. 2000;50(Suppl. 1):39–43
  16. Druckmann R, Rohr UD. Igf-1 in gynaecology and obstetrics: update 2002. Maturitas. 2002;41(Suppl. 1):S65–S83
  17. Borgfeldt C, Andolf E. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand. 2004;83:395–400
  18. Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med. 2001;345:266–275
  19. Ogawa S, Kaku T, Amada S, et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol. 2000;77:298–304
  20. Vigano P, Somigliana E, Parazzini F, et al. Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer. Fertil Steril. 2007;88:588–593
  21. Varma R, Rollason T, Gupta JK, et al. Endometriosis and the neoplastic process. Reproduction. 2004;127:293–304
  22. Baxter SW, Thomas EJ, Campbell IG. Gstm1 null polymorphism and susceptibility to endometriosis and ovarian cancer. Carcinogenesis. 2001;22:63–65
  23. Martini M, Ciccarone M, Garganese G, et al. Possible involvement of hmlh1, p16(ink4a) and pten in the malignant transformation of endometriosis. Int J Cancer. 2002;102:398–406
  24. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene pten in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60:7052–7056
  25. Obata K, Hoshiai H. Genetic analysis of endometriosis and ovarian cancer, Nippon Rinsho. 2001;59(Suppl. 1):217–220
  26. Otsuka J, Okuda T, Sekizawa A, et al. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. Med Electron Microsc. 2004;37:188–192
  27. Dinulescu DM, Ince TA, Quade BJ, et al. Role of k-ras and pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005;11:63–70
  28. Prefumo F, Venturini PL, Fulcheri E. Analysis of p53 and c-erbb-2 expression in ovarian endometrioid carcinomas arising in endometriosis. Int J Gynecol Pathol. 2003;22:83–88
  29. Sainz de la Cuesta R, Izquierdo M, Canamero M, et al. Increased prevalence of p53 overexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis. Eur J Obstet Gynecol Reprod Biol. 2004;113:87–93
  30. Bulun SE, Simpson ER. Aromatase expression in women's cancers. Adv Exp Med Biol. 2008;630:112–132
  31. Bulun SE, Zeitoun K, Takayama K, et al. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer. 1999;6:293–301
  32. Bulun SE, Zeitoun KM, Takayama K, et al. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update. 2000;6:413–418
  33. Seeger H, Wallwiener D, Kraemer E, et al. Estradiol metabolites are potent mitogenic substances for human ovarian cancer cells. Eur J Gynaecol Oncol. 2005;26:383–385
  34. O'Donnell AJ, Macleod KG, Burns DJ, et al. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer. 2005;12:851–866
  35. Matsuzaki S, Canis M, Murakami T, et al. Expression of the cyclin-dependent kinase inhibitor p27kip1 in eutopic endometrium and peritoneal endometriosis. Fertil Steril. 2001;75:956–960
  36. Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril. 2001;75:1–10
  37. Meresman GF, Vighi S, Buquet RA, et al. Apoptosis and expression of bcl-2 and bax in eutopic endometrium from women with endometriosis. Fertil Steril. 2000;74:760–766
  38. Mizumoto H, Saito T, Ashihara K, et al. Expression of matrix metalloproteinases in ovarian endometriomas: immunohistochemical study and enzyme immunoassay. Life Sci. 2002;71:259–273
  39. Ueda M, Yamashita Y, Takehara M, et al. Gene expression of adhesion molecules and matrix metalloproteinases in endometriosis. Gynecol Endocrinol. 2002;16:391–402
  40. Moseson M, Koenig KL, Shore RE, et al. The influence of medical conditions associated with hormones on the risk of breast cancer. Int J Epidemiol. 1993;22:1000–1009
  41. Weiss HA, Brinton LA, Potischman NA, et al. Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol. 1999;28:816–823
  42. Schairer C, Persson I, Falkeborn M, et al. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer. 1997;70:150–154
  43. Brinton LA, Westhoff CL, Scoccia B, et al. Causes of infertility as predictors of subsequent cancer risk. Epidemiology. 2005;16:500–507
  44. Bertelsen L, Mellemkjaer L, Frederiksen K, et al. Risk for breast cancer among women with endometriosis. Int J Cancer. 2007;120:1372–1375
  45. Henderson BE, Ross RK, Judd HL, et al. Do regular ovulatory cycles increase breast cancer risk?. Cancer. 1985;56:1206–1208
  46. Fathalla MF. Incessant ovulation–a factor in ovarian neoplasia?. Lancet. 1971;2:163
  47. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 us case-control studies. Ii. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136:1184–1203
  48. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331:771–776
  49. Mosgaard BJ, Lidegaard O, Kjaer SK, et al. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril. 1997;67:1005–1012
  50. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2002;155:217–224
  51. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol. 2004;103:1194–1203
  52. Jensen A, Sharif H, Frederiksen K, et al. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ. 2009;338:b249
  53. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril. 2004;82:405–414
  54. Willemsen W, Kruitwagen R, Bastiaans B, et al. Ovarian stimulation and granulosa-cell tumour. Lancet. 1993;341:986–988
  55. Tennent BJ, Shultz KL, Sundberg JP, et al. Ovarian granulosa cell tumorigenesis in swr-derived f1 hybrid mice: preneoplastic follicular abnormality and malignant disease progression. Am J Obstet Gynecol. 1990;163:625–634
  56. Hahlin M, Crona N, Knutsson F, et al. Human granulosa cell tumor: stimulation of steroidogenesis by gonadotropins in vitro. Gynecol Oncol. 1991;40:201–206
  57. Unkila-Kallio L, Leminen A, Tiitinen A, et al. Nationwide data on falling incidence of ovarian granulosa cell tumours concomitant with increasing use of ovulation inducers. Hum Reprod. 1998;13:2828–2830
  58. Shushan A, Paltiel O, Iscovich J, et al. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril. 1996;65:13–18
  59. Parazzini F, Negri E, La Vecchia C, et al. Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol. 1998;68:226–228
  60. Adewole IF, Babarinsa IA, Thomas JO, et al. Ovarian cancer associated with ovulation induction: a case report. Afr J Med Med Sci. 1997;26:203–204
  61. Dietl J. Ovulation and ovarian cancer. Lancet. 1991;338:445
  62. Ron E, Lunenfeld B, Menczer J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1987;125:780–790
  63. Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1998;147:1038–1042
  64. Doyle P, Maconochie N, Beral V, et al. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod. 2002;17:2209–2213
  65. Orgeas CC, Sanner K, Hall P, et al. Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study. Am J Obstet Gynecol. 2009;200(72):e71–77
  66. Gauthier E, Paoletti X, Clavel-Chapelon F. Breast cancer risk associated with being treated for infertility: results from the French e3n cohort study. Hum Reprod. 2004;19:2216–2221
  67. Burkman RT, Tang MT, Malone KE, et al. Infertility drugs and the risk of breast cancer: findings from the national institute of child health and human development women's contraceptive and reproductive experiences study. Fertil Steril. 2003;79:844–851
  68. Brinton LA, Scoccia B, Moghissi KS, et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod. 2004;19:2005–2013
  69. Terry KL, Willett WC, Rich-Edwards JW, et al. Clomiphene citrate use and reduced incidence of premenopausal breast cancer. Am J Epidemiol. 2004;159:2615
  70. Rossing MA, Daling JR, Weiss NS, et al. Risk of breast cancer in a cohort in infertile women. Gynecol Oncol. 1996;60:3–7
  71. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project p-1 study. J Natl Cancer Inst. 1998;90:1371–1388
  72. Benshushan A, Paltiel O, Brzezinski A, et al. Ovulation induction and risk of endometrial cancer: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2001;98:53–57
  73. Althuis MD, Scoccia B, Lamb EJ, et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol. 2005;193:668–674
  74. Venn A, Watson L, Lumley J, et al. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet. 1995;346:995–1000
  75. Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 1999;354:1586–1590
  76. Lerner-Geva L, Geva E, Lessing JB, et al. The possible association between in vitro fertilization treatments and cancer development. Int J Gynecol Cancer. 2003;13:23–27
  77. Pappo I, Lerner-Geva L, Halevy A, et al. The possible association between ivf and breast cancer incidence. Ann Surg Oncol. 2008;15:1048–1055
  78. Katz D, Paltiel O, Peretz T, et al. Beginning IVF treatments after age 30 increases the risk of breast cancer: results of a case-control study. Breast J. 2008;14:517–522

PII: S1521-6934(09)00107-2

doi: 10.1016/j.bpobgyn.2009.08.004

Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 24, Issue 1 , Pages 39-50 , February 2010

Article Tools